Clinical research
A few days ago, CNBC reported that five patients, three in Moderna’s and two in Pfizer’s Phase III trials, had experienced more severe, although transient side effects.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).
New long-term safety and efficacy data highlights the medication’s capabilities in allowing patients to maintain fewer migraine days over a period of five years.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
AstraZeneca’s Phase III COVID-19 vaccine study in the United States is being further delayed due to the U.S. FDA wanting to take a more thorough look at information related to the trial.
Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).
PF-06939926 is currently being evaluated to determine the safety and efficacy of this gene therapy in boys with DMD.
The trial was initially placed on hold in November 2019 due to safety concerns.
Moderna published second interim analysis of its open-label Phase I trial of its COVID-19 vaccine, mRNA-1273, in The New England Journal of Medicine.
PRESS RELEASES